HomePRQR • NASDAQ
ProQR Therapeutics NV
$2.02
5.76%
+0.11 Today
After Hours:
$2.06
(1.98%)+0.040
Closed: Aug 13, 6:46:24 PM UTC-4 · USD · NASDAQ · Disclaimer
Financials
Income Statement
-10M-5M05M
Revenue
Net Income
Revenue
Net income
(EUR)Jun 2025Y/Y change
Revenue
3.98M-38.48%
Operating expense
16.22M61.26%
Net income
-12.18M-352.41%
Net profit margin
-306.39-635.28%
Earnings per share
EBITDA
-11.57M-300.62%
Effective tax rate
-0.15%
050M100M150M
Total Assets
Total Liabilities
Total assets
Total liabilities
(EUR)Jun 2025Y/Y change
Cash and short-term investments
119.77M24.56%
Total assets
137.54M16.51%
Total liabilities
70.55M-17.19%
Total equity
66.98M
Shares outstanding
105.34M
Price to book
2.98
Return on assets
-21.18%
Return on capital
-34.09%
020M40M60M
Net Change in Cash
Net change in cash
(EUR)Jun 2025Y/Y change
Net income
-12.18M-352.41%
Cash from operations
-11.40M-82.24%
Cash from investing
-101.00K62.17%
Cash from financing
-293.00K-3.90%
Net change in cash
-12.65M-87.59%
Free cash flow
-6.82M-2,807.79%
StockUS listed security
Previous close
$1.91
Day range
$1.92 - $2.09
Year range
$1.08 - $4.62
Market cap
212.79M USD
Avg Volume
249.20K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
ProQR Therapeutics NV is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer. Wikipedia
Founded
2012
Website
Employees
166
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Finance
Search
Clear search
Close search
Main menu
Google apps